<--- Back to Details
First PageDocument Content
Membrane biology / Phospholipids / Sphingomyelin / Niemann–Pick disease / Lysosome / Lysosomal storage disease / Niemann-Pick disease /  SMPD1-associated / Sphingomyelin phosphodiesterase 1 / Biology / Lipid storage disorders / Rare diseases
Date: 2008-10-21 11:41:51
Membrane biology
Phospholipids
Sphingomyelin
Niemann–Pick disease
Lysosome
Lysosomal storage disease
Niemann-Pick disease
SMPD1-associated
Sphingomyelin phosphodiesterase 1
Biology
Lipid storage disorders
Rare diseases

National Niemann-Pick Disease Foundation Grant #48 Six-Month Progress: Lay Summary – Edward H. Schuchman, PhD The goal of our research is to create a new mouse model of Type A NPD. This mouse will make an abnormal (or

Add to Reading List

Source URL: www.nnpdf.org

Download Document from Source Website

File Size: 24,50 KB

Share Document on Facebook

Similar Documents

How one patient with a rare disease coped with his genetic disorder

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

CrossMark_Color_flat+click

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is  HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

MUCOPOLYSACCHARIDOSES  Rare Diseases Unit of the Finnish Association of People with Physical Disabilities  Support for this guide was provided by Genzyme.

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document